Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (2477)	1/6/2001 12:50:22 AM
From: scaram(o)uche	Respond to of 52153

It is easy to make big bucks in biotech, largely because there are people like Cramer who only know the names of a few stocks/companies. Among those few names, they don't understand the science at any of them. They therefore make mistakes. Find companies that are developing good, under-respected molecules that address large markets..... do you think that Fed easing -- or Cramer -- is going to hurt those companies? Chuckle. And..... for how many years has Cramer been a counter-indicator? quote.yahoo.com

To: JMarcus who wrote (2477)	1/6/2001 1:13:38 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

>> Is this article by Jim Cramer the kind of refreshing analysis you crave? (not) << Actually..... yes. It is really, really, really easy to make money in biotech. Wait for "Cramers" to come along. Ask yourself this question..... how many times has he called Miljenko for advice in the past two years? If the answer is zero, since (1) he's in the business of providing investment advice, and (2) he's flapping his lips about biotech, how smart can he be? There will be a whole bunch of investors and money managers sitting and listening to presentations in SF next week. They will be trying to do the SMART thing; they will be trying to determine if the delta between cash in the bank and market cap is a true "value" reflection for the patents and preclinical or clinical work. If the answer is "no", jerks like Cramer will be swamped. The answer, flat out obvious, is "no" for lots of companies. Cramer can't find them. We do. [Scott..... cool!]